Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905880 | 0.81 | MAPK8 (0.40) | SQORMAPK8MAPK9CTSSCTSK | |
| SCHEMBL4908567 | 0.73 | ADORA2A (0.57) | ADORA1ADORA2ACTSSCTSKADORA2B | |
| SCHEMBL4907550 | 0.72 | BRAF (0.42) | ADORA1ADORA2AMAPK14ADORA2B | |
| SCHEMBL4898242 | 0.69 | CTSL (0.50) | ADORA1ADORA2ACTSSCTSK | |
| SCHEMBL4904086 | 0.69 | ACHE (0.43) | SQORMAPK8MAPK9CTSSCTSK | |
| SCHEMBL4898493 | 0.69 | ADORA1 (0.50) | ADORA1ADORA2ACTSSCTSKADORA2B | |
| SCHEMBL4900864 | 0.68 | MAPT (0.45) | ADORA1ADORA2A | |
| SCHEMBL4911779 | 0.68 | CTSK (0.40) | ADORA1ADORA2AMAPK14CTSSCTSK | |
| SCHEMBL4909542 | 0.68 | CTSS (0.47) | ADORA1ADORA2ACTSSCTSKADORA2B | |
| SCHEMBL4911380 | 0.67 | ADORA1 (0.39) | ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | ADORA1 529/4885ADORA2A 837/4885MAPK14 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.